Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial

The study aimed to determine whether a regimen of doravirine, lamivudine, and tenofovir disoproxil fumarate results in less weight gain compared to a regimen of dolutegravir, emtricitabine, and tenofovir alafenamide while maintaining similar levels of viral suppression in ART-naive adults with HIV. The findings indicated that both regimens achieved comparable viral suppression rates at 48 weeks, but the doravirine-based regimen was associated with significantly less weight gain. This suggests that the doravirine regimen may be a preferable option for managing weight-related concerns in individuals starting HIV treatment.